Estrella Historical Balance Sheet
| ESLAW Stock | 0.09 0.0008 0.89% |
Trend analysis of Estrella Immunopharma balance sheet accounts such as Total Stockholder Equity of 2.8 M or Accounts Payable of 0.0 provides information on Estrella Immunopharma's total assets, liabilities, and equity, which is the actual value of Estrella Immunopharma to its prevalent stockholders. By breaking down trends over time using Estrella Immunopharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Estrella Immunopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Estrella Immunopharma is a good buy for the upcoming year.
Estrella |
About Estrella Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Estrella Immunopharma at a specified time, usually calculated after every quarter, six months, or one year. Estrella Immunopharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Estrella Immunopharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Estrella currently owns. An asset can also be divided into two categories, current and non-current.
Estrella Immunopharma Balance Sheet Chart
Add Fundamental
Accounts Payable
An accounting item on the balance sheet that represents Estrella Immunopharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Estrella Immunopharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Estrella Immunopharma balance sheet. This account contains Estrella Immunopharma investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Estrella Immunopharma fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Other Current Assets
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.Most accounts from Estrella Immunopharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Estrella Immunopharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Estrella Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Estrella Stock please use our How to Invest in Estrella Immunopharma guide.At this time, Estrella Immunopharma's Total Assets are fairly stable compared to the past year. Net Invested Capital is likely to climb to about 4.5 M in 2024, whereas Total Stockholder Equity is likely to drop slightly above 2.8 M in 2024.
| 2010 | 2022 | 2023 | 2024 (projected) | Other Stockholder Equity | 34.3K | 19.3M | 23.8M | 15.8M | Other Current Assets | 833.3K | 11.6K | 288.8K | 302.3K |
Estrella Immunopharma balance sheet Correlations
Click cells to compare fundamentals
Estrella Immunopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Estrella Stock Analysis
When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.